We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mirum Pharmaceuticals (MIRM) Moves 5.1% Higher: Will This Strength Last?
Read MoreHide Full Article
Mirum Pharmaceuticals, Inc. (MIRM - Free Report) shares soared 5.1% in the last trading session to close at $92.38. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.4% loss over the past four weeks.
Last month, Mirum completed enrollment in its phase III EXPAND study evaluating Livmarli (maralixibat) for cholestatic pruritus in patients aged six months and older with rare liver diseases, including biliary atresia. The study’s primary goal is to assess the reduction in itch severity by week 20, with additional biomarkers as secondary endpoints, and results are expected in the fourth quarter of 2026. The study could support a label expansion for Livmarli, an oral IBAT inhibitor already approved for Alagille syndrome and certain progressive familial intrahepatic cholestasis patients. This has likely been driving the stock price gain for the company.
This company is expected to post quarterly loss of $0.40 per share in its upcoming report, which represents a year-over-year change of -33.3%. Revenues are expected to be $149.1 million, up 33.6% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Mirum Pharmaceuticals, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on MIRM going forward to see if this recent jump can turn into more strength down the road.
Mirum Pharmaceuticals belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Ocugen (OCGN - Free Report) , closed the last trading session 3.4% higher at $1.81. Over the past month, OCGN has returned -9.8%.
Ocugen's consensus EPS estimate for the upcoming report has changed +17.9% over the past month to -$0.05. Compared to the company's year-ago EPS, this represents no change. Ocugen currently boasts a Zacks Rank of #3 (Hold).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Mirum Pharmaceuticals (MIRM) Moves 5.1% Higher: Will This Strength Last?
Mirum Pharmaceuticals, Inc. (MIRM - Free Report) shares soared 5.1% in the last trading session to close at $92.38. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.4% loss over the past four weeks.
Last month, Mirum completed enrollment in its phase III EXPAND study evaluating Livmarli (maralixibat) for cholestatic pruritus in patients aged six months and older with rare liver diseases, including biliary atresia. The study’s primary goal is to assess the reduction in itch severity by week 20, with additional biomarkers as secondary endpoints, and results are expected in the fourth quarter of 2026. The study could support a label expansion for Livmarli, an oral IBAT inhibitor already approved for Alagille syndrome and certain progressive familial intrahepatic cholestasis patients. This has likely been driving the stock price gain for the company.
This company is expected to post quarterly loss of $0.40 per share in its upcoming report, which represents a year-over-year change of -33.3%. Revenues are expected to be $149.1 million, up 33.6% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Mirum Pharmaceuticals, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on MIRM going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Mirum Pharmaceuticals belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Ocugen (OCGN - Free Report) , closed the last trading session 3.4% higher at $1.81. Over the past month, OCGN has returned -9.8%.
Ocugen's consensus EPS estimate for the upcoming report has changed +17.9% over the past month to -$0.05. Compared to the company's year-ago EPS, this represents no change. Ocugen currently boasts a Zacks Rank of #3 (Hold).